MP Wattjes and J Killestein lesion, LME is a long-lasting radiological finding (at least over several years), suggesting, perhaps, impaired recovery of the blood-meningeal barrier in a persistently inflammatory niche.
Some caveats need to be considered as well. In existing autopsy cases that allow radiological-pathological correlation, LME is associated with lymphocytes and monocytes/macrophages gathered around leptomeningeal venules and spatially associated with subpial cortical demyelination; 5 however, the spatial link between LME and cortical demyelinated lesions has not been conclusively shown in vivo. In addition, by definition, LME on postcontrast T2-FLAIR is not sensitive to inflamed meningeal areas with a partially intact blood-meningeal barrier or in which gadolinium does not concentrate within the subarachnoid space. Finally, LME does not appear to respond to treatments routinely used for MS, though there are preliminary indications that corticosteroids might induce transient modulation of the finding.
These caveats are not unusual when new findings are reported through the application of new techniques; there are numerous open research questions that need to be properly addressed. Thus, the key phrase in the title of this article is "should become": with proper investment of research resources, imaging of meningeal inflammation will eventually be a critical part of the clinical routine in MS imaging. 6 There is probably no other topic in the field of in vivo neuroimaging in multiple sclerosis (MS) than "the detection of leptomeningeal inflammation (LME)" causing so much interest but also so much controversies in the scientific community. There is no doubt that there is leptomeningeal inflammation present in MS patients as conclusively been demonstrated by histopathological studies. 1 Recent magnetic resonance imaging (MRI) studies applying contrast-enhanced three-dimensional (3D) fluid-attenuated inversion recovery (FLAIR) images at higher magnetic field strengths (⩾3 T) detected small lesions with a leptomeningeal distribution pattern suggestive of LME. [2] [3] [4] [5] [6] In addition, some studies suggested that these lesions suggestive of LME are associated with neurodegenerative changes such as cortical grey matter atrophy as well as with clinical progression makers. [7] [8] [9] Obviously, this topic attracts such a high publicity so that the focus goes currently beyond MS including other inflammatory diseases such as neuromyelitis optica spectrum disorders (NMOSD), immune-mediated encephalitis, and Susac syndrome. 10, 11 In terms of MRI acquisition protocol, the assessment of LME could be easily implemented in the clinical practice. The MAGNIMS (www.magnims.eu) guidelines recommend postcontrast 3D FLAIR sequences for diagnostic and treatment monitoring purposes, and this sequence seems to be the most established MR acquisition technique for the detection of LME. 12, 13 However, the crucial question is whether the detection and monitoring of LME suggestive of inflammation is useful and helpful in the clinical routine setting or not. First of all, the term "leptomeningeal enhancement" applied to imaging findings obtained from contrastenhanced 3D FLAIR acquisitions is misleading. The term "enhancement" derives from T1-weighted images and is not used for FLAIR sequences on a regular basis. In the brain tissue, contrast enhancement indicates the disruption of the blood-brain barrier. In MS patients, the acute and active inflammatory white matter lesions are frequently associated with a temporary blood-brain barrier disruption leading to contrast enhancement. In the leptomeninges, however, we do not exactly know where this "enhancement" seen on contrast-enhanced 3D FLAIR really derives from. Is it based on leaky vessels due to perivascular inflammation or based on fibrotic tissue (e.g. meningeal fibrosis)? Interestingly, in contrast to MS white matter lesions, the LME seen on MRI can stay there for months and years raising the question of the underlying histopathological background. 2 Another important issue is the reliability and reproducibility of the radiological assessment. The available literature is exclusively based on single-center studies with limited data on inter-rater and intra-rater agreement. One study presented very impressive inter-rater agreement values regarding the presence and extent of LME reflected by Cohen's kappa of 0.78 and an intraclass correlation coefficient (ICC) of 0.93, respectively. However, these findings concerning rather small lesions in difficult anatomic areas such as the leptomeningeal space have not been reproduced so far. 8 Even if the reliability and reproducibility regarding the detection of LME might be acceptable in high expert level centers, it remains questionable and doubtable whether this will be the case in centers with a lower expertise in this field.
At this time, we do not know the clinical and prognostic consequences of LME detection on MRI in MS patients. The fact that LME is also observed in other inflammatory diseases of the central nervous systems limits its value as a potential marker for MS differential diagnosis. There is currently no convincing evidence that LME does have prognostic value in terms of disease activity and disability progression. Studies addressing this topic are very scarce and are based on a very limited number of patients. This statement is further supported by the fact that the whole concept that LME is significantly linked to cortical demyelination with clinical consequences in terms of disease progression is still under debate. 14 In a recently published commentary, we described this situation as a "déjà vu" because we had a similar situation more than 10 years ago when the improved detection of cortical grey matter MS lesions on double inversion recovery and/or higher magnetic field strengths attracted major attention. 15 Although cortical grey matter pathology detected on MRI has major diagnostic and prognostic power in MS, it has not entered the routine clinical setting and has never been implemented as standard outcome measure for clinical trials. The most important reason for this is probably the lack of standardization regarding image acquisition and interpretation. Keeping this in mind we have to confess that we are only on the starting point of investigating the histopathological background and the clinical relevance of LME in MS. We should take it for granted that these issues need to be sorted out first before this imaging marker is ready to enter the arena of clinical routine in order to facilitate MS diagnosis and patient monitoring.
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